01/09/2020 (Agence Europe) – The international phase 3 clinical trial testing the effectiveness of Kevzara, a drug co-developed by the French and American companies Sanofi and Regeneron to treat rheumatoid arthritis, has not produced conclusive results. The news was announced by Agence France-Presse (AFP) on Tuesday 1 September. The trial evaluating the effectiveness of Kevzara (sarilumab) in treating serious forms of Covid-19 included 420 patients and was conducted in Argentina, Brazil,...